RiboBio Secures Third Consecutive Spot on 'Future Healthcare 100' List Amid IPO Filing

Recently, the "2025 Future Healthcare and Pharmaceutical 100 Strong" list was grandly unveiled in Suzhou. With its continuous efforts and breakthroughs in the small nucleic acid field, Ribo Life Science once again claimed the title of "Top 100 Innovative Pharmaceuticals and Biologics in China" for the third time.

"Top 100 in Future Healthcare and Pharmaceutical" is aimed at non-listed companies in the healthcare sector, based on the VB100 valuation model. In addition to considering the company's most recent round of valuation, it further evaluates the growth and annual performance of candidate companies across four primary indicators—human resources, knowledge resources, key partner resources, and market performance—as well as 17 secondary indicators. Special emphasis is placed on the innovation and breakthroughs achieved by companies in technology, products, and therapies.

In recent years, Ribo Life Science has forged ahead amidst the adversities of industry and capital winters. Through its solid globalization strategy, differentiated pipeline, innovative technology layout, and continuous external cooperation, the company has gained recognition from both the industry and investors. Building on years of accumulation in the small nucleic acid field, the company has established a comprehensive moat in areas such as technology platforms, product pipelines, intellectual property, and talent aggregation, highlighting its global competitiveness in small nucleic acid pharmaceuticals. As the small nucleic acid industry enters a period of vigorous development, Ribo Life Science will remain committed to meeting unmet clinical needs of patients worldwide. The company will continue to uphold its science-driven, pioneering, and innovative corporate spirit, rapidly advancing the clinical development of multiple proprietary pipelines with BIC/FIC potential, striving to realize its vision of becoming a globally leading innovative small nucleic acid pharmaceutical enterprise.